Benserazide·HCl (Ro 4-4602) is a small molecule inhibitor of extracerebral DDC (aromatic L-aminoacid decarboxylase), also known as DOPA decarboxylase. This protein is responsible for decarboxylating L-DOPA to dopamine, 5-hydroxytryptophan to serotonin, and tryptophan to tryptamine. L-DOPA is delivered directly to subjects suffering from a dopaminergic dysfunction such as in Parkinson's disease and dopamine-responsive dystonia - L-DOPA is the natural precursor to dopamine and freely passes the blood brain barrier, while dopamine itself does not. Inhibition of the extracerebral decarboxylation of L-DOPA into dopamine by Benserazide increases the availability of L-DOPA for movement into the brain and subsequent conversion to dopamine. Benserazide·HCl (Ro 4-4602) is an inhibitor of TH and TPH.
1. Pinder, R.M., et al. 1976. Drugs. 11: 329-377. PMID: 782834 2. Marion, M.H., et al. 1987. Adv Neurol. 45: 493-496. PMID: 3548262 3. Merims, D., et al. 2008. Parkinsonism Relat. Disord. 14: 273-280. PMID: 17988927
Soluble in water (10 mg/ml), DMSO, and methanol. Insoluble in 100% ethanol, and acetone.
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn